Effect of selective inhibition of renal inducible nitric oxide synthase on renal blood flow and function in experimental hyperdynamic sepsis

Critical Care Medicine

Volumn 40, Issue 8, 2012, Pages 2368-2375

  Ishikawa, Ken ^a   Calzavacca, Paolo ^a   Bellomo, Rinaldo ^b   Bailey, Michael ^c   May, Clive N ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

acute kidney failure; inducible nitric oxide synthase; nitric oxide; renal blood flow; selective inducible nitric oxide synthase inhibitor; sepsis

Indexed keywords

AMINOGUANIDINE; CREATININE; INDUCIBLE NITRIC OXIDE SYNTHASE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N(G) NITROARGININE METHYL ESTER;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; HYPERDYNAMIC SEPSIS; INTERVENTION STUDY; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL ARTERY; SEPSIS; SHEEP;

ACUTE KIDNEY INJURY; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; GUANIDINES; HEMODYNAMICS; INFUSIONS, INTRA-ARTERIAL; KIDNEY; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE II; RENAL ARTERY; RENAL CIRCULATION; SEPSIS; SHEEP;

EID: 84864278158     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3182514be9     Document Type: Article

References (36)

1. Uchino S, Kellum JA, Bellomo R, et al: Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294:813-818.
2. Bagshaw SM, George C, Bellomo R: ANZICS Database Management Committee: Early acute kidney injury and sepsis: A multicentre evaluation. Crit Care 2008; 12:R47.
3. Bellomo R, Wan L, Langenberg C, et al: Septic acute kidney injury: New concepts. Nephron Exp Nephrol 2008; 109:e95-e100.
4. Groeneveld AB, Sipkema P: Interaction of oxyradicals, antioxidants, and nitric oxide during sepsis. Crit Care Med 2000; 28:2161-2162. (Pubitemid 30428806)
5. Burney S, Caulfield JL, Niles JC, et al: The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res 1999; 424:37-49. (Pubitemid 29101606)
6. Szabó C, Mitchell JA, Thiemermann C, et al: Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 1993; 108:786-792. (Pubitemid 23067954)
7. Krishnagopalan S, Kumar A, Parrillo JE, et al: Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002; 8:376-388.
8. Enkhbaatar P, Murakami K, Shimoda K, et al: Inducible nitric oxide synthase dimerization inhibitor prevents cardiovascular and renal morbidity in sheep with combined burn and smoke inhalation injury. Am J Physiol Heart Circ Physiol 2003; 285:H2430-H2436. (Pubitemid 37443059)
9. López A, Lorente JA, Steingrub J, et al: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30. (Pubitemid 38125559)
10. Ishikawa K, Bellomo R, May CN: The impact of intrarenal nitric oxide synthase inhibition on renal blood flow and function in mild and severe hyperdynamic sepsis. Crit Care Med 2010; 39:770-776.
11. Langenberg C, Wan L, Egi M, et al: Renal blood flow in experimental septic acute renal failure. Kidney Int 2006; 69:1996-2002. (Pubitemid 43924263)
12. Heemskerk S, Masereeuw R, Russel FG, et al: Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury. Nat Rev Nephrol 2009; 5:629-640.
13. . Garvey EP, Oplinger JA, Furfine ES, et al: 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric-oxide synthase in vitro and in vivo. J Biol Chem 1997; 272:4959-4963. (Pubitemid 27090046)
14. Boer R, Ulrich WR, Klein T, et al: The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes. Mol Pharmacol 2000; 58:1026-1034.
15. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: Structure, function and inhibition. Biochem J 2001; 357(Pt 3):593-615.
16. Matejovic M, Radermacher P, Tugtekin I, et al: Effects of selective iNOS inhibition on gut and liver O2-exchange and energy metabolism during hyperdynamic porcine endotoxemia. Shock 2001; 16:203-210. (Pubitemid 33598198)
17. Laszlo F, Whittle BJ: Actions of isoform-selective and non-selective nitric oxide synthase inhibitors on endotoxin-induced vascular leakage in rat colon. Eur J Pharmacol 1997; 334:99-102. (Pubitemid 27417815)
18. Rairigh RL, Parker TA, Ivy DD, et al: Role of inducible nitric oxide synthase in the pulmonary vascular response to birth-related stimuli in the ovine fetus. Circ Res 2001; 88:721-726. (Pubitemid 32378142)
19. Enkhbaatar P, Murakami K, Shimoda K, et al: Inhibition of neuronal nitric oxide synthase by 7-nitroindazole attenuates acute lung injury in an ovine model. Am J Physiol Regul Integr Comp Physiol 2003; 285:R366-R372. (Pubitemid 36898906)
20. Strand OA, Leone A, Giercksky KE, et al: Nitric oxide indices in human septic shock. Crit Care Med 2000; 28:2779-2785.
21. MacMicking J, Xie QW, Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15:323-350. (Pubitemid 27169284)
22. Schwartz D, Brasowski E, Raskin Y, et al: The outcome of non-selective vs selective nitric oxide synthase inhibition in lipopolysaccharide treated rats. J Nephrol 2001; 14:110-114. (Pubitemid 32433016)
23. Howes LG, Brillante DG: Expert opinion on tilarginine in the treatment of shock. Expert Opin Investig Drugs 2008; 17:1573-1580.
24. Cauwels A: Nitric oxide in shock. Kidney Int 2007; 72:557-565. (Pubitemid 47312788)
25. Schwartz D, Mendonca M, Schwartz I, et al: Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 1997; 100:439-448. (Pubitemid 27349092)
26. Rosselet A, Feihl F, Markert M, et al: Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med 1998; 157:162-170. (Pubitemid 28071278)
27. Johannes T, Mik EG, Klingel K, et al: Effects of 1400W and/or nitroglycerin on renal oxygenation and kidney function during endotoxaemia in anaesthetised rats. Clin Exp Pharmacol Physiol 2009 Apr.
28. Matejovic M, Krouzecky A, Martinkova V, et al: Selective inducible nitric oxide synthase inhibition during long-term hyperdynamic porcine bacteremia. Shock 2004; 21:458-465.
29. Koizumi T, Ogasawara H, Yamamato H, et al: Effect of ONO1714, a specific inducible nitric oxide synthase inhibitor, on lung lymph filtration and gas exchange during endotoxemia in unanesthetized sheep. Anesthesiology 2004; 101:59-65. (Pubitemid 38833263)
30. Wan L, Langenberg C, Bellomo R, et al: Angiotensin II in experimental hyperdynamic sepsis. Crit Care 2009; 13:R190.
31. Gordon AC, Russell JA, Walley KR, et al: The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010; 36:83-91.
32. Morelli A, Ertmer C, Westphal M: "Terlipressin in the treatment of septic shock: The earlier the better"? Best Pract Res Clin Anaesthesiol 2008; 22:317-321. (Pubitemid 351816779)
33. Wray GM, Millar CG, Hinds CJ, et al: Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/dysfunction, caused by endotoxin. Shock 1998; 9:329-335. (Pubitemid 128463880)
34. Ito S, Arima S, Ren YL, et al. Endotheliumderived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 1993; 91:2012-2019. (Pubitemid 23141473)
35. Southan GJ, Szabo C: Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996; 51:383-394. (Pubitemid 26071171)
36. Nilsson BO: Biological effects of aminoguanidine: An update. Inflamm Res 1999; 48:509-515.